The Priority Review

The stream · Daily digest

The stream: Saturday, October 3, 2026

6 briefs from the Federal Register and ClinicalTrials.gov, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Regulation · 3

  1. FDA requests nominations for voting members of advisory committees

    The agency is seeking qualified individuals to fill scientific, technical, professional, and other voting-member positions. The notice was published October 1, 2026.

    Source: Federal Register notice, October 1, 2026

  2. FDA requests nominations for consumer representatives on advisory committees

    The FDA is requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2026, with interest letters due by November 16, 2026.

    Source: Federal Register notice, October 1, 2026

  3. FDA determines ISTURISA not withdrawn from sale

    The FDA has determined that ISTURISA (osilodrostat) tablets, 10 mg, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications for osilodrostat tablets, 10 mg if all other legal and regulatory requirements are met.

    Source: Federal Register notice, September 30, 2026

Policy · 2

  1. CMS announces $90 Medicare Part B premium rebate for 20.8 million beneficiaries

    CMS announced a $90 Medicare Improvement Fund Premium Rebate for eligible Medicare Part B beneficiaries, with most receiving a direct deposit around October 8, 2026. The rebate is available to 20.8 million Americans in Original Medicare Part B who are not receiving Medicaid premium assistance or paying an Income-Related Monthly Adjustment Amount.

    Source: CMS fact sheet, October 3, 2026

  2. CMS highlights Texas employers' use of CHOICE Arrangement

    CMS, SBA and Take Command showcased how Texas businesses are adopting the CHOICE Arrangement to give employees tax-advantaged contributions toward individual health coverage. The model offers employers predictability and employees more choice, according to the press release.

    Source: CMS press release, September 30, 2026

Clinical trials · 1

  1. Boehringer Ingelheim registers Phase 3b trial of Survodutide in MASLD

    This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 600 participants and planned start date is October 23, 2026.

    Source: ClinicalTrials.gov registry record, September 30, 2026